Collegium Pharmaceutical Accounts Payable Over Time
| COLL Stock | USD 30.79 0.83 2.77% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Collegium Pharmaceutical Performance and Collegium Pharmaceutical Correlation. Collegium |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collegium Pharmaceutical. If investors know Collegium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collegium Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.49) | Earnings Share 2.34 | Revenue Per Share 18.538 | Quarterly Revenue Growth 0.165 | Return On Assets 0.0968 |
The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collegium Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Collegium Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collegium Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Accounts Payable Analysis
Compare Collegium Pharmaceutical and related stocks such as Phibro Animal Health, ANI Pharmaceuticals, and Procaps Group SA Accounts Payable Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PAHC | 32.6 M | 67.9 M | 57.9 M | 59.6 M | 63.1 M | 60.2 M | 56.9 M | 59.5 M | 73.2 M | 66.1 M | 68.4 M | 95.6 M | 73.9 M | 85.6 M | 64 M |
| ANIP | 68.8 K | 3.2 M | 1.1 M | 1.4 M | 2.7 M | 2.1 M | 3.4 M | 3.6 M | 8.9 M | 14.6 M | 11.3 M | 23 M | 29.3 M | 36.7 M | 38.5 M |
| PROC | 94.2 M | 94.2 M | 94.2 M | 94.2 M | 94.2 M | 94.2 M | 94.2 M | 94.2 M | 94.2 M | 94.2 M | 84.5 M | 70.2 M | 81.5 M | 73.3 M | 66.1 M |
| AMPH | 17.7 M | 17.7 M | 17.7 M | 20.4 M | 10.2 M | 13.9 M | 16.2 M | 16.6 M | 87.4 M | 77.1 M | 24.4 M | 22.2 M | 20.5 M | 25.4 M | 32.3 M |
| ALKS | 1.2 M | 18.4 M | 18.3 M | 19.5 M | 32.3 M | 37.4 M | 46.3 M | 55.5 M | 39.8 M | 54.3 M | 46 M | 55.7 M | 32.8 M | 65.6 M | 68.9 M |
| EOLS | 230 K | 230 K | 230 K | 230 K | 230 K | 230 K | 2.9 M | 445 K | 1.6 M | 5.8 M | 9.6 M | 6.1 M | 8.9 M | 4.3 M | 4.9 M |
| PBH | 5.3 M | 26.7 M | 51.4 M | 48.3 M | 46.1 M | 38.3 M | 70.2 M | 61.4 M | 56.6 M | 62.4 M | 46 M | 55.8 M | 62.7 M | 39 M | 42 M |
| RGC | 154 M | 174.5 M | 157 M | 170.2 M | 165.7 M | 229.7 M | 194.8 M | 232.2 M | 232.2 M | 232.2 M | 232.2 M | 232.2 M | 232.2 M | 267 M | 200 M |
| PCRX | 11.8 M | 3.4 M | 2.6 M | 3.1 M | 6.8 M | 8.7 M | 7.5 M | 14.7 M | 14.4 M | 12.8 M | 10.4 M | 10.5 M | 15.2 M | 15.7 M | 10.4 M |
| ITCI | 596 K | 596 K | 41.6 K | 3.4 M | 2.1 M | 1.6 M | 3.8 M | 6.2 M | 14 M | 7.4 M | 5.5 M | 8.7 M | 10.4 M | 11.5 M | 6.4 M |
| RDY | 10.3 M | 9.5 B | 118.6 B | 10.5 B | 10.7 B | 12.3 B | 13.4 B | 16.1 B | 14.6 B | 10.7 B | 12.7 B | 16 B | 17.9 B | 21.5 B | 14.3 B |
Collegium Pharmaceutical and related stocks such as Phibro Animal Health, ANI Pharmaceuticals, and Procaps Group SA Accounts Payable description
An accounting item on the balance sheet that represents Collegium Pharmaceutical obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Collegium Pharmaceutical are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.My Equities
My Current Equities and Potential Positions
| Collegium Pharmaceutical | COLL |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 30.79
Check out Collegium Pharmaceutical Performance and Collegium Pharmaceutical Correlation. For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Collegium Pharmaceutical technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.